Rhythm begins clinical trials of Setmelanotide for treatment of Prader-Willi syndrome obesity

Biopharmaceutical firm Rhythm has started two Phase II clinical trials to assess the safety and effectiveness of setmelanotide (RM-493) for rare genetic disorders of obesity.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news